Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
出版年份 2019 全文链接
标题
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-22
DOI
10.1186/s40425-019-0599-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
- (2018) Jessica Wagner et al. JOURNAL OF CLINICAL INVESTIGATION
- Monoamines in glioblastoma: complex biology with therapeutic potential
- (2017) Seamus Patrick Caragher et al. NEURO-ONCOLOGY
- Dopamine receptor D2 is correlated with gastric cancer prognosis
- (2017) Jiasheng Mu et al. Oncology Letters
- Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
- (2017) Varun V. Prabhu et al. PLoS One
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Discovery and clinical introduction of first-in-class imipridone ONC201
- (2016) Joshua E. Allen et al. Oncotarget
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
- (2015) Joshua E Allen et al. Molecular Cancer
- Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
- (2015) Jie Li et al. Oncotarget
- Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor
- (2014) Joanna Mikulak et al. JOURNAL OF IMMUNOLOGY
- Dopamine Receptors Modulate Cytotoxicity of Natural Killer Cells via cAMP-PKA-CREB Signaling Pathway
- (2013) Wei Zhao et al. PLoS One
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells
- (2012) Eleftherios Sachlos et al. CELL
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search